Skip to main content

Aratana Therapeutics (PETX) - Get Aratana Therapeutics, Inc. Report shares were down 11.3% to $5.52 in premarket trading on Thursday after the Leawood, Kan.-based company on Wednesday announced the pricing of a registered direct offering. The company said it has inked a securities purchase agreement with several institutional investors for the issuance and sale of a total of 5 million shares at  $5.25 apiece.

Shares of Trevena (TRVN) - Get Trevena, Inc. Report were up 9.1% to $3.70. The King of Prussia, Pa.-based firm on Thursday reported a first-quarter net loss attributable to common stockholders of $20.7 million, or $0.36 per share, versus a net loss of $17.8 million, or $0.35 per share, in the year-ago period.

Other biotech movers include Sangamo Therapeutics (SGMO) - Get Sangamo Therapeutics, Inc. Report , up 4.4% to $4.70. The Richmond, Calif.-based firm said Thursday it was notified by the U.S. Food and Drug Administration of special regulatory designations for three of the company's clinical programs: a rare pediatric disease designation for SB-913 in vivo genome editing treatment for mucopolysaccharidosis type II, an orphan drug designation for SB-525 cDNA gene therapy for hemophilia A and a fast track designation for SB-FIX in vivo genome editing treatment for hemophilia B.

TheStreet Recommends

Jim Cramer and the AAP team give their analysis on Facebook's FB first-quarter results. Find out what they are telling their investment club members. Get a free trial subscription to Action Alerts PLUS.

Meanwhile, over on Real Money, Cramer highlights some of the priceless moments from Tesla's TSLA earnings call. Get his insights with a free trial subscription to Real Money.